Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy

Itzhak Avital; Björn L.D.M. Brücher; Aviram Nissan; Alexander Stojadinovic

doi:10.1016/j.soc.2012.07.004

Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy

Itzhak Avital, Björn L.D.M. Brücher, Aviram Nissan, Alexander Stojadinovic

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Upwards of 40% of patient with colorectal cancer develop peritoneal carcinomatosis (CRCPC). Of the 2500 patients reported in the literature, 1000 underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in median survival of 22 to 63 months. However, level I data from prospective randomized trials are limited. Further trials are indicated to identify peritoneal carcinomatosis in at-risk patients early in the natural history of the disease and confirm the efficacy of multimodality therapy (CRS/HIPEC/systemic therapy) in those with CRCPC amenable to CRS in the modern era of novel targeted and cytotoxic systemic therapy.

Original language	English
Pages (from-to)	665-688
Number of pages	24
Journal	Surgical Oncology Clinics of North America
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2012.07.004
State	Published - 1 Oct 2012
Externally published	Yes

Keywords

CRS
Carcinomatosis
Clinical trials
Colorectal cancer
HIPEC
Oxaliplatin and mitomycin
Prospective
Randomized

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.soc.2012.07.004

Cite this

@article{bd8a87258af74828b5c0e21d633b0cb1,

title = "Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy",

abstract = "Upwards of 40% of patient with colorectal cancer develop peritoneal carcinomatosis (CRCPC). Of the 2500 patients reported in the literature, 1000 underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in median survival of 22 to 63 months. However, level I data from prospective randomized trials are limited. Further trials are indicated to identify peritoneal carcinomatosis in at-risk patients early in the natural history of the disease and confirm the efficacy of multimodality therapy (CRS/HIPEC/systemic therapy) in those with CRCPC amenable to CRS in the modern era of novel targeted and cytotoxic systemic therapy.",

keywords = "CRS, Carcinomatosis, Clinical trials, Colorectal cancer, HIPEC, Oxaliplatin and mitomycin, Prospective, Randomized",

author = "Itzhak Avital and Br{\"u}cher, {Bj{\"o}rn L.D.M.} and Aviram Nissan and Alexander Stojadinovic",

note = "Funding Information: Support: This clinical research effort was supported, in part, by the United States Military Cancer Institute, Washington, DC and the Henry M. Jackson Foundation, Rockville, MD. ",

year = "2012",

month = oct,

day = "1",

doi = "10.1016/j.soc.2012.07.004",

language = "English",

volume = "21",

pages = "665--688",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy

AU - Avital, Itzhak

AU - Brücher, Björn L.D.M.

AU - Nissan, Aviram

AU - Stojadinovic, Alexander

N1 - Funding Information: Support: This clinical research effort was supported, in part, by the United States Military Cancer Institute, Washington, DC and the Henry M. Jackson Foundation, Rockville, MD.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Upwards of 40% of patient with colorectal cancer develop peritoneal carcinomatosis (CRCPC). Of the 2500 patients reported in the literature, 1000 underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in median survival of 22 to 63 months. However, level I data from prospective randomized trials are limited. Further trials are indicated to identify peritoneal carcinomatosis in at-risk patients early in the natural history of the disease and confirm the efficacy of multimodality therapy (CRS/HIPEC/systemic therapy) in those with CRCPC amenable to CRS in the modern era of novel targeted and cytotoxic systemic therapy.

AB - Upwards of 40% of patient with colorectal cancer develop peritoneal carcinomatosis (CRCPC). Of the 2500 patients reported in the literature, 1000 underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in median survival of 22 to 63 months. However, level I data from prospective randomized trials are limited. Further trials are indicated to identify peritoneal carcinomatosis in at-risk patients early in the natural history of the disease and confirm the efficacy of multimodality therapy (CRS/HIPEC/systemic therapy) in those with CRCPC amenable to CRS in the modern era of novel targeted and cytotoxic systemic therapy.

KW - CRS

KW - Carcinomatosis

KW - Clinical trials

KW - Colorectal cancer

KW - HIPEC

KW - Oxaliplatin and mitomycin

KW - Prospective

KW - Randomized

UR - http://www.scopus.com/inward/record.url?scp=84866786500&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2012.07.004

DO - 10.1016/j.soc.2012.07.004

M3 - Review article

AN - SCOPUS:84866786500

SN - 1055-3207

VL - 21

SP - 665

EP - 688

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this